IDA Act of 2026
Summary
The IDA Act of 2026, an early-stage bill referred to committee, would exempt state dental benefit laws from ERISA preemption, allowing states to regulate employer-sponsored dental plans. The bill authorizes no funding and is procedural in nature. Near-term market impact is minimal, but if enacted, it would increase administrative costs for large health insurers like UnitedHealth, Cigna, and Humana that administer dental benefits.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The IDA Act is an early-stage bill with no funding; it would shift dental benefit regulation from federal to state level.
- 2.If enacted, the bill increases administrative costs for health insurers that manage dental benefits, but the impact is small relative to their total revenue.
- 3.No immediate market impact; investors should monitor committee progress for signs of momentum.
Market Implications
The IDA Act of 2026 is unlikely to move markets in its current early stage. If it gains traction, health insurers with dental administration exposure (, $CI, $HUM) could face modest margin compression from state-level compliance costs, but the effect is small relative to their core medical insurance businesses. No bullish signals for any publicly traded company. Investors should treat this as a low-probability, low-impact event.
Full Analysis
The IDA Act of 2026 (HR7931) was introduced on March 12, 2026, by Rep. Van Drew (R-NJ) and referred to the House Committee on Education and Workforce. The bill is in early legislative stages with no committee hearings or markups yet. It has 9 cosponsors, indicating modest bipartisan support but no strong momentum. The bill amends ERISA Section 514(b) to exempt state laws related to dental benefits from federal preemption, effective 18 months after enactment. This would allow states to impose their own regulations on employer-sponsored dental plans, including self-funded plans currently shielded by ERISA.
The bill authorizes zero dollars — it is a regulatory change, not a spending bill. The money trail is indirect: if enacted, state dental benefit mandates (e.g., network adequacy, claims processing standards, reimbursement floors) would apply to ERISA plans, increasing compliance costs for plan administrators. The primary cost burden falls on health insurers and third-party administrators that manage dental benefits for employers. No federal funds are involved.
Structural winners: dental service organizations and dental providers may benefit from stronger state-level consumer protections and reimbursement standards, but no publicly traded pure-play dental benefit companies exist. Structural losers: large health insurers with dental administration businesses — UnitedHealth (Optum), Cigna (Cigna Dental), and Humana — face increased compliance costs. However, dental benefits represent a small fraction of these companies' total revenue (estimated <5% for each), so the impact is limited. Dental-focused insurers like Delta Dental (private) are not publicly traded.
No real market data is provided for stock prices. The competitive landscape is unchanged at this stage. The bill's early status means no immediate market action is warranted.
Timeline: The bill must pass the House Education and Workforce Committee, then the full House, then the Senate, then be signed by the President. Given the 18-month implementation delay, even if enacted, effects would not be felt until late 2027 at the earliest. The current Congress (119th) runs through 2027, so passage is possible but uncertain.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Exemption from ERISA preemption for state dental benefit laws
Who must act
Employer-sponsored group health plans that include dental benefits
What happens
State-level dental benefit regulations will apply to self-funded ERISA plans, increasing compliance costs and administrative complexity for plan administrators
Stock impact
Cigna's dental business (Cigna Dental) is a significant segment; state-level regulation increases administrative burden and may pressure margins on dental plan administration, but dental is a smaller portion of Cigna's overall revenue compared to medical
What the bill does
Exemption from ERISA preemption for state dental benefit laws
Who must act
Employer-sponsored group health plans that include dental benefits
What happens
State-level dental benefit regulations will apply to self-funded ERISA plans, increasing compliance costs and administrative complexity for plan administrators
Stock impact
Humana offers dental benefits through employer plans; state-level regulation increases administrative burden and may pressure margins on dental plan administration, but dental is a very small portion of Humana's overall revenue
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Access to Genetic Counselor Services Act of 2025
HELP Copays Act
Daniel J. Harvey, Jr. and Adam Lambert Improving Servicemember Transition to Reduce Veteran Suicide Act
Great American Healthcare Plan
PBM Act
PBM Act
Ensuring Rural Health Care Access for Military and Tribal Families Act
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.